TNFerade, an innovative cancer immunotherapeutic

Indian Journal of Pharmacology

Volumn 47, Issue 5, 2015, Pages 479-483

  Kali, Arunava ^a  

^a MAHATMA GANDHI MEDICAL COLLEGE AND RESEARCH INSTITUTE   (India)

Author keywords

Cancer immunotherapy; gene therapy; TNFerade; tumor necrosis factor

Indexed keywords

GOLNERMINOGENE PRADENOVEC; DNA; TNFERASEBIOLOGIC; TUMOR NECROSIS FACTOR;

ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; DISEASE FREE SURVIVAL; DRUG CARCINOGENICITY; DRUG MECHANISM; HUMAN; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; ANIMAL; DISEASE COURSE; GENE THERAPY; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES; SURVIVAL RATE;

ANIMALS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA; GENETIC THERAPY; HUMANS; IMMUNOTHERAPY; NEOPLASMS; SURVIVAL RATE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84944050841     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.165190     Document Type: Review

References (32)

1. GLOBOCAN 2012. Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Lyon, France: International Agency for Research on Cancer; 2012. Available from: http://www.globocan.iarc.fr/Pages/fact-sheets-cancer.aspx. [Last accessed on 2015 Jan 20]
2. Chang GJ. Challenge of primary tumor management in patients with stage IV colorectal cancer. J Clin Oncol 2012;30:3165-6
3. Iacovino JR. Breast cancer micrometastasis. J Insur Med 2014;44:72
4. Kim E, Telford JJ. Advances in endoscopic ultrasound, part 2: Therapy. Can J Gastroenterol 2009;23:691-8
5. Advantages and Disadvantages of Cancer Treatment; 2011. Available from: http://www.cancerlive.net/cancer-treatment/advantages-and-disadvantagesof-cancer-treatment/. [Last accessed on 2014 Oct 26]
6. Merlano M, Mattiot VP. Future chemotherapy and radiotherapy options in head and neck cancer. Expert Rev Anticancer Ther 2006;6:395-403
7. Cavazzana-Calvo M, Thrasher A, Mavilio F. The future of gene therapy. Nature 2004;427:779-81
8. Kircheis R, Wagner E. Technology evaluation: TNFerade, GenVec. Curr Opin Mol Ther 2003;5:437-47
9. Varian and GenVec Reach Agreement to Jointly Develop New Therapy Products/Collaboration on Combining Radiotherapy with Novel Gene Constructs Aimed at Enhanced Therapy Techniques, New Products for Fighting Cancer. GenVec Inc Press Release; 1998. Available from: http://www.prnewswire. com/news-releases/varian-and-genvec-reach-agreement-to-jointly-develop-new-therapy-products-77337602.html. [Last accessed on 2015 Jan 20]
10. Abbas AK, Lichtman AH. Basic Immunology: Functions and Disorders of the Immune System. Philadelphia, USA: Saunders/Elsevier; 2010
11. Oh YC, Jeong YH, Kim T, Cho WK, Ma JY. Anti-inflammatory effect of Artemisiae annuae herba in lipopolysaccharide-stimulated RAW 264.7 Cells. Pharmacogn Mag 2014;10 Suppl 3:S588-95
12. Kirana H, Jali MV, Srinivasan BP. The study of aqueous extract of Ficus religiosa Linn. on cytokine TNF-A in type 2 diabetic rats. Pharmacognosy Res 2011;3:30-4
13. Liu X, Zhang XF, Zheng ZW, Lu H, Wu X, Huang C, et al. The effect of chemotherapy combined with recombination mutant human tumor necrosis factor on advanced cancer. J Transl Med 2004;2:33
14. Kufe D, Weichselbaum R. Radiation therapy: Activation for gene transcription and the development of genetic radiotherapy-therapeutic strategies in oncology. Cancer Biol Ther 2003;2:326-9
15. Albelda SM, Sterman DH. TNFerade to the rescue? Guidelines for evaluating phase I cancer gene transfer trials. J Clin Oncol 2004;22:577-9
16. Chang KJ, Reid T, Senzer N, Swisher S, Pinto H, Hanna N, et al. Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer. Gastrointest Endosc 2012;75:1139-46. e2
17. Hecht JR, Farrell JJ, Senzer N, Nemunaitis J, Rosemurgy A, Chung T, et al. EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: A phase I/II study. Gastrointest Endosc 2012;75:332-8
18. Hallahan DE, Mauceri HJ, Seung LP, Dunphy EJ, Wayne JD, Hanna NN, et al. Spatial and temporal control of gene therapy using ionizing radiation. Nat Med 1995;1:786-91
19. Rasmussen H, Rasmussen C, Lempicki M, Durham R, Brough D, King CR, et al. TNFerade Biologic: Preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene. Cancer Gene Ther 2002;9:951-7
20. Sharma A, Mani S, Hanna N, Guha C, Vikram B, Weichselbaum RR, et al. Clinical protocol. An open-label, phase I, dose-escalation study of tumor necrosis factor-alpha (TNFerade Biologic) gene transfer with radiation therapy for locally advanced, recurrent, or metastatic solid tumors. Hum Gene Ther 2001;12:1109-31
21. TNFerade Gene Therapy Causes Tumor Shrinkage at Lowest. Available from: http://www.prnewswire.com/news-releases/tnferade-gene-therapy-causes-tumorshrinkage-at-lowest-doses-during-phase-i-clinical-trials-74090882. html. [Last accessed on 2015 Jan 20]
22. TNFerade Gene Therapy Causes Tumor Shrinkage at Lowest Doses During Phase I Clinical Trials; 2001. Available from: http://www.prnewswire. com/news-releases/tnferade-gene-therapy-causes-tumor-shrinkage-atlowest-doses-during-phase-i-clinical-trials-74090882. html. [Last accessed on 2015 Jan 20]
23. Seiwert TY, Darga T, Haraf D, Blair EA, Stenson K, Cohen EE, et al. A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. Ann Oncol 2013;24:769-76
24. Mundt AJ, Vijayakumar S, Nemunaitis J, Sandler A, Schwartz H, Hanna N, et al. A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities. Clin Cancer Res 2004;10:5747-53
25. Gupta VK, Park JO, Jaskowiak NT, Mauceri HJ, Seetharam S, Weichselbaum RR, et al. Combined gene therapy and ionizing radiation is a novel approach to treat human esophageal adenocarcinoma. Ann Surg Oncol 2002;9:500-4
26. Citrin D, Camphausen K, Wood BJ, Quezado M, Denobile J, Pingpank JF, et al. A pilot feasibility study of TNFerade™ biologic with capecitabine and radiation therapy followed by surgical resection for the treatment of rectal cancer. Oncology 2010;79:382-8
27. Murugesan SR, King CR, Osborn R, Fairweather WR, O'Reilly EM, Thornton MO, et al. Combination of human tumor necrosis factor-alpha (hTNF-alpha) gene delivery with gemcitabine is effective in models of pancreatic cancer. Cancer Gene Ther 2009;16:841-7
28. Weichselbaum RR, Kufe D. Translation of the radio-and chemo-inducible TNFerade vector to the treatment of human cancers. Cancer Gene Ther 2009;16:609-19
29. McLoughlin JM, McCarty TM, Cunningham C, Clark V, Senzer N, Nemunaitis J, et al. TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: Surgical experience and long-term follow-up. Ann Surg Oncol 2005;12:825-30
30. Senzer N, Mani S, Rosemurgy A, Nemunaitis J, Cunningham C, Guha C, et al. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: A phase I study in patients with solid tumors. J Clin Oncol 2004;22:592-601
31. Herman JM, Wild AT, Wang H, Tran PT, Chang KJ, Taylor GE, et al. Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: Final results. J Clin Oncol 2013;31:886-94
32. Douglas JT. Adenoviral vectors for gene therapy. Mol Biotechnol 2007;36:71-80